[go: up one dir, main page]

PE20210287A1 - Anti-cd25 para el agotamiento de celulas tumorales especificas - Google Patents

Anti-cd25 para el agotamiento de celulas tumorales especificas

Info

Publication number
PE20210287A1
PE20210287A1 PE2020001292A PE2020001292A PE20210287A1 PE 20210287 A1 PE20210287 A1 PE 20210287A1 PE 2020001292 A PE2020001292 A PE 2020001292A PE 2020001292 A PE2020001292 A PE 2020001292A PE 20210287 A1 PE20210287 A1 PE 20210287A1
Authority
PE
Peru
Prior art keywords
depletion
tumor cells
specific tumor
antibodies
present disclosure
Prior art date
Application number
PE2020001292A
Other languages
English (en)
Inventor
Anne Goubier
Corzo Beatriz Goyenechea
Josephine Salimu
Kevin Moulder
Pascal Merchiers
Mark Brown
Bianka Prinz
James Geoghegan
Sergio Quezada
Original Assignee
Cancer Research Tech Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804027.9A external-priority patent/GB201804027D0/en
Priority claimed from PCT/EP2018/056312 external-priority patent/WO2018167104A1/en
Priority claimed from GBGB1804029.5A external-priority patent/GB201804029D0/en
Priority claimed from GBGB1804028.7A external-priority patent/GB201804028D0/en
Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd
Publication of PE20210287A1 publication Critical patent/PE20210287A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgacion proporciona secuencias de anticuerpos encontradas en anticuerpos que se unen a CD25 humana. En particular, la presente divulgacion proporciona secuencias de anticuerpos anti-CD25 humanos, que no bloquean la union de CD25 a IL-2 ni la senalizacion de IL-2. Los anticuerpos y las porciones de union a antigeno de los mismos que incluyen dichas secuencias se pueden usar en composiciones farmaceuticas y metodos de tratamiento, en particular para tratar el cancer
PE2020001292A 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas PE20210287A1 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862642230P 2018-03-13 2018-03-13
US201862642232P 2018-03-13 2018-03-13
US201862642248P 2018-03-13 2018-03-13
US201862642243P 2018-03-13 2018-03-13
US201862642218P 2018-03-13 2018-03-13
GBGB1804027.9A GB201804027D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion
GBGB1804029.5A GB201804029D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
GBGB1804028.7A GB201804028D0 (en) 2018-03-13 2018-03-13 Anti-CD25 antibody agents
PCT/EP2019/056248 WO2019175216A1 (en) 2018-03-13 2019-03-13 Anti-cd25 for tumour specific cell depletion

Publications (1)

Publication Number Publication Date
PE20210287A1 true PE20210287A1 (es) 2021-02-11

Family

ID=67903878

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2020001299A PE20210288A1 (es) 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas
PE2020001292A PE20210287A1 (es) 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas
PE2020001320A PE20210289A1 (es) 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020001299A PE20210288A1 (es) 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020001320A PE20210289A1 (es) 2018-03-13 2019-03-13 Anti-cd25 para el agotamiento de celulas tumorales especificas

Country Status (14)

Country Link
US (11) US11802161B2 (es)
EP (8) EP3765503B1 (es)
JP (8) JP7451414B2 (es)
KR (3) KR20200131862A (es)
CN (8) CN112020516B (es)
AU (3) AU2019233575A1 (es)
BR (3) BR112020016519A2 (es)
CA (3) CA3088671A1 (es)
CR (3) CR20200466A (es)
MA (1) MA51993A (es)
PE (3) PE20210288A1 (es)
SG (3) SG11202008784RA (es)
TW (3) TW201938588A (es)
WO (8) WO2019175216A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
PL3440109T3 (pl) * 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
CN108795858A (zh) * 2017-04-28 2018-11-13 深圳宾德生物技术有限公司 高抗癌活性t细胞的筛选方法和应用
SG11202008784RA (en) 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2020234399A1 (en) * 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021228218A1 (zh) * 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
CA3201423A1 (en) * 2020-11-13 2022-05-19 Ibio, Inc. Cd25 antibodies
WO2022106663A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
CA3199006A1 (en) * 2020-11-20 2022-05-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-cd25 antibodies
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
EP4288100A1 (en) 2021-02-02 2023-12-13 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
KR20230154012A (ko) 2021-03-01 2023-11-07 에프. 호프만-라 로슈 아게 신규 바이오마커 및 이의 용도
WO2023016455A1 (zh) 2021-08-09 2023-02-16 南京诺艾新生物技术有限公司 重组抗人cd25抗体及其应用
EP4392455A4 (en) * 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES
WO2023031403A1 (en) 2021-09-02 2023-03-09 F. Hoffmann-La Roche Ag Antibodies for the treatment of aml
JP2024532485A (ja) * 2021-09-03 2024-09-05 ノヴァロック バイオセラピューティクス， リミテッド Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質
TW202340250A (zh) 2022-01-17 2023-10-16 大陸商諾納生物（蘇州）有限公司 標靶ｃｄ２５的抗體及其製備方法和應用
US20250257141A1 (en) 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist
CN115197321B (zh) * 2022-06-02 2023-08-18 四川大学 靶向cd25的抗体及其用途
CN115181181B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种抗cd25的单域抗体及其应用
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
WO2024006965A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
CN116004636B (zh) * 2023-01-10 2024-03-12 广西师范大学 一种不结合红细胞的差异化cd47核酸适体及其应用
EP4662238A1 (en) 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof
WO2024192065A1 (en) * 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
IL320593A (en) 2023-03-29 2025-07-01 Daiichi Sankyo Co Ltd Anti-CD25 antibody and anti-CD25 antibody conjugate
WO2024213046A1 (en) * 2023-04-11 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Anti-cd25 antibody and uses thereof
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA2505991C (en) 2002-11-15 2018-02-27 Genmab A/S Human monoclonal antibodies against cd25
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004074437A2 (en) 2003-02-14 2004-09-02 University Of Southern California Compositions and methods for cancer immunotherapy
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
WO2011077245A2 (en) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
CN106432495A (zh) 2010-07-22 2017-02-22 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3216804A3 (en) * 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
AU2014232416B2 (en) * 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
RU2015144033A (ru) 2013-03-15 2017-04-26 Эббви Байотекнолоджи Лтд. Антитела против cd25 и их применения
EP3003390B1 (en) * 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
BR112017000703A2 (pt) 2014-07-16 2017-11-14 Genentech Inc métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CA2957387A1 (en) 2014-08-07 2016-02-11 Hyogo College Of Medicine Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
US11147652B2 (en) 2014-11-13 2021-10-19 Align Technology, Inc. Method for tracking, predicting, and proactively correcting malocclusion and related issues
WO2016079050A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
WO2016081748A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
SG10202006538TA (en) * 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
ES2786651T3 (es) 2015-02-19 2020-10-13 Compugen Ltd Anticuerpos anti-PVRIG y métodos de uso
DK3274370T3 (da) * 2015-03-23 2020-02-17 Bayer Pharma AG Anti-ceacam6-antistoffer og anvendelser deraf
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201806861SA (en) * 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
ES2801873T3 (es) * 2016-03-04 2021-01-14 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
PL3440109T3 (pl) * 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
MA45233A (fr) * 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations
JP6831651B2 (ja) 2016-07-04 2021-02-17 川崎重工業株式会社 ワークの袋詰め装置
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US11119165B2 (en) 2017-06-28 2021-09-14 North Carolina State University Office of Research Commercialization Photonic band-gap resonator for magnetic resonance applications
WO2019008386A1 (en) 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
SG11202008784RA (en) 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
UA129536C2 (uk) 2018-03-13 2025-05-28 Туск Терап'Ютікс Лтд Анти-cd25 для виснаження пухлиноспецифічних клітин
KR20200003558A (ko) 2018-07-02 2020-01-10 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치
KR102080909B1 (ko) 2018-07-06 2020-02-24 한국수력원자력 주식회사 원자로의 해체 시스템

Also Published As

Publication number Publication date
CN112218891B (zh) 2024-07-16
CA3088246A1 (en) 2019-09-19
JP7451414B2 (ja) 2024-03-18
CN112020514B (zh) 2024-08-20
KR20200131862A (ko) 2020-11-24
US11851494B2 (en) 2023-12-26
CN112020515A (zh) 2020-12-01
EP3765502A1 (en) 2021-01-20
CN112020514A (zh) 2020-12-01
CN112041345A (zh) 2020-12-04
US11873341B2 (en) 2024-01-16
EP3765511A1 (en) 2021-01-20
WO2019175222A1 (en) 2019-09-19
US11919960B2 (en) 2024-03-05
AU2019233581B2 (en) 2025-08-28
EP3765503A1 (en) 2021-01-20
TW201938588A (zh) 2019-10-01
JP2021516974A (ja) 2021-07-15
SG11202008699WA (en) 2020-10-29
SG11202008733YA (en) 2020-10-29
PE20210288A1 (es) 2021-02-11
US20190284287A1 (en) 2019-09-19
KR20200131861A (ko) 2020-11-24
EP3765502C0 (en) 2024-08-07
BR112020016501A2 (pt) 2021-01-26
US10745485B2 (en) 2020-08-18
EP3765504B1 (en) 2024-07-31
BR112020016499A2 (pt) 2021-01-26
CN112020513B (zh) 2024-08-16
JP2021516975A (ja) 2021-07-15
JP2021515565A (ja) 2021-06-24
EP3765502B1 (en) 2024-08-07
US10752691B2 (en) 2020-08-25
JP7563978B2 (ja) 2024-10-08
CN112074536A (zh) 2020-12-11
CA3088671A1 (en) 2019-09-19
BR112020016519A2 (pt) 2020-12-15
MA51993A (fr) 2021-01-20
JP7510348B2 (ja) 2024-07-03
US20210047420A1 (en) 2021-02-18
WO2019175215A1 (en) 2019-09-19
CN112020515B (zh) 2024-07-16
US20200407454A1 (en) 2020-12-31
AU2019233576A1 (en) 2020-09-17
US20210009702A1 (en) 2021-01-14
SG11202008784RA (en) 2020-10-29
US20190300613A1 (en) 2019-10-03
JP2021515568A (ja) 2021-06-24
JP2021516976A (ja) 2021-07-15
US11814434B2 (en) 2023-11-14
EP3765504A1 (en) 2021-01-20
WO2019175224A1 (en) 2019-09-19
JP2021516973A (ja) 2021-07-15
EP3765506B1 (en) 2024-04-24
WO2019175220A1 (en) 2019-09-19
EP3765506C0 (en) 2024-04-24
US20190322752A1 (en) 2019-10-24
WO2019175223A1 (en) 2019-09-19
US11802160B2 (en) 2023-10-31
CA3088659A1 (en) 2019-09-19
EP3765511B1 (en) 2024-07-24
EP3765511C0 (en) 2024-07-24
CN112020512A (zh) 2020-12-01
KR20200131286A (ko) 2020-11-23
JP7474701B2 (ja) 2024-04-25
TW201940515A (zh) 2019-10-16
CR20200465A (es) 2020-11-17
US11787866B2 (en) 2023-10-17
CN112020513A (zh) 2020-12-01
CN112074536B (zh) 2024-09-10
WO2019175216A1 (en) 2019-09-19
WO2019175217A1 (en) 2019-09-19
CN112020516A (zh) 2020-12-01
EP3765504C0 (en) 2024-07-31
JP7451415B2 (ja) 2024-03-18
EP3765505C0 (en) 2023-09-27
WO2019175226A1 (en) 2019-09-19
US20210040221A1 (en) 2021-02-11
AU2019233575A1 (en) 2020-09-17
JP7563979B2 (ja) 2024-10-08
CN112218891A (zh) 2021-01-12
EP3765507B1 (en) 2024-04-24
EP3765505B1 (en) 2023-09-27
EP3765510A1 (en) 2021-01-20
EP3765507C0 (en) 2024-04-24
EP3765506A1 (en) 2021-01-20
US11802161B2 (en) 2023-10-31
US20210009704A1 (en) 2021-01-14
JP7565797B2 (ja) 2024-10-11
JP2021533726A (ja) 2021-12-09
EP3765507A1 (en) 2021-01-20
CR20200467A (es) 2020-11-17
EP3765503C0 (en) 2024-05-01
AU2019233581A1 (en) 2020-09-03
EP3765505A1 (en) 2021-01-20
US20210009703A1 (en) 2021-01-14
CN112020516B (zh) 2025-01-03
PE20210289A1 (es) 2021-02-11
CR20200466A (es) 2020-11-11
US11697688B2 (en) 2023-07-11
JP2021515566A (ja) 2021-06-24
US10738125B2 (en) 2020-08-11
EP3765503B1 (en) 2024-05-01
US20210054084A1 (en) 2021-02-25
CN112020512B (zh) 2024-12-31
TW202003034A (zh) 2020-01-16
CN112041345B (zh) 2025-01-03
KR102909650B1 (ko) 2026-01-08
US20210009699A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
PE20210288A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
EA201892294A1 (ru) Антитела и композиции против tim-3
NI201700012A (es) Inhibidores de la proteina quinasa c y métodos de su uso
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CR20190477A (es) Versión optimizada para fc de anticuerpo anti-cd25 para la reducción celular específica de tumor
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
EA202092302A1 (ru) Антитела к trem-1 и их применения
CL2021002603A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores (divisional de la solicitud no. 202002340)
MX2021015228A (es) Metodos y composiciones para mejorar resultados de pacientes con cancer.
AR114278A1 (es) Agentes anticuerpos anti-cd25
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
AR117579A1 (es) Anticuerpos específicos para gucy2c y sus usos
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
CR20140095A (es) Un conjugado citotóxico ca6 antigeno-específico y métodos para utilizar el mismo